Companies Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals CEO salary & total pay, FY2023: $1M
Syros Pharmaceuticals (SYRS) CEO salary, fiscal 2023: Conley Chee was paid a salary of $479,092 and $1,041,697 in total compensation. Free brief. Every figure links to the company’s own filing.
Syros Pharmaceuticals, Inc. no longer files a proxy statement; its last pay data is FY2023.
Conley Chee's complete compensation dossier
A PDF and a CSV sent to your email: Conley Chee's pay in every fiscal year Syros Pharmaceuticals, Inc. reported it, line by line, with Conley Chee's equity grants and Syros Pharmaceuticals, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $3,487,880FY2022
- $1,041,697FY2023
CEO total pay was $1,041,697 in fiscal 2023 (Conley Chee), down from $3,487,880 in fiscal 2022 (Nancy Simonian, the CEO that year).
FY2023: salary $479,092 · bonus $0 · stock awards $369,460 · option awards $0
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Nancy Simonian | $635,385 | $0 | $477,174 | $0 | $318,986 | $0 | $5,237 | $1,436,782 |
| Former President & Chief Executive Officer | ||||||||
| Conley Chee | 479,092 | 0 | 369,460 | 0 | 192,455 | 0 | 690 | 1,041,697 |
| President & Chief Executive Officer | ||||||||
| Eric Olson | 409,791 | 0 | 140,700 | 0 | 0 | 0 | 385,277 | 935,768 |
| Former Chief Scientific Officer | ||||||||
| David Roth | 516,154 | 0 | 160,800 | 0 | 197,600 | 0 | 1,980 | 876,534 |
| Chief Medical Officer | ||||||||
| Jason Haas | 485,185 | 0 | 160,800 | 0 | 185,744 | 0 | 1,290 | 833,019 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Nancy Simonian | $1,436,782 | $3,487,880 | — | ↓ −2,051,098 |
| Conley Chee | 1,041,697 | — | — | — |
| Eric Olson | 935,768 | 1,668,669 | — | ↓ −732,901 |
| David Roth | 876,534 | 1,759,093 | — | ↓ −882,559 |
| Jason Haas | 833,019 | 1,416,010 | — | ↓ −582,991 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company aims to reward value creation for stockholders and attract, motivate, and retain executive officers by aligning their interests with those of stockholders through a mix of short-term and long-term performance-based incentives. The compensation committee considers market comparables, individual and corporate performance, and the desire to foster long-term commitment while managing dilution.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Conley Chee | Option | 20,248 | 15,752 | 48.1 | — |
| Conley Chee | Option | 4,580 | 5,420 | 15.9 | — |
| Conley Chee | Option | 22,250 | 22,250 | 6.73 | — |
| Conley Chee | RSU | — | 6,000 | — | 46,740 |
| Conley Chee | RSU | — | 17,000 | — | 132,430 |
| Conley Chee | RSU | — | 35,000 | — | 272,650 |
| Conley Chee | RSU | — | 86,000 | — | 669,940 |
| Conley Chee | PSU | — | 35,000 | — | 272,650 |
| Conley Chee | PSU | — | 86,000 | — | 669,940 |
| David Roth | Option | 9,003 | 396 | 75.4 | — |
| David Roth | Option | 8,428 | 3,471 | 114.1 | — |
| David Roth | Option | 5,724 | 6,775 | 15.9 | — |
| David Roth | Option | 24,875 | 24,875 | 6.73 | — |
| David Roth | RSU | — | 6,000 | — | 46,740 |
| David Roth | RSU | — | 20,000 | — | 155,800 |
| David Roth | RSU | — | 18,875 | — | 147,036 |
| David Roth | RSU | — | 40,000 | — | 311,600 |
| David Roth | PSU | — | 40,000 | — | 311,600 |
| David Roth | Option | 22,364 | — | 90.8 | — |
| David Roth | Option | 6,349 | — | 109 | — |
| David Roth | Option | 7,499 | — | 109 | — |
| David Roth | Option | 7,499 | — | 67.1 | — |
| Eric Olson | Option | 453 | — | 13.88 | — |
| Eric Olson | Option | 3,477 | — | 30.38 | — |
| Eric Olson | Option | 2,584 | — | 30.4 | — |
| Eric Olson | Option | 6,349 | — | 109 | — |
| Eric Olson | Option | 7,499 | — | 109 | — |
| Eric Olson | Option | 7,499 | — | 67.1 | — |
| Eric Olson | Option | 8,415 | — | 75.4 | — |
| Eric Olson | Option | 6,069 | — | 114.1 | — |
| Eric Olson | Option | 3,955 | — | 15.9 | — |
| Jason Haas | Option | 40,618 | 34,382 | 45.4 | — |
| Jason Haas | Option | 5,725 | 6,775 | 15.9 | — |
| Jason Haas | Option | 24,875 | 24,875 | 6.73 | — |
| Jason Haas | RSU | — | 6,000 | — | 46,740 |
| Jason Haas | RSU | — | 18,875 | — | 147,036 |
| Jason Haas | RSU | — | 40,000 | — | 311,600 |
| Jason Haas | PSU | — | 40,000 | — | 311,600 |
| Nancy Simonian | Option | 17,185 | 20,314 | 15.9 | — |
| Nancy Simonian | Option | 57,500 | 57,500 | 6.73 | — |
| Nancy Simonian | RSU | — | 18,000 | — | 140,220 |
| Nancy Simonian | RSU | — | 40,000 | — | 311,600 |
| Nancy Simonian | RSU | — | 40,125 | — | 312,574 |
| Nancy Simonian | RSU | — | 118,700 | — | 924,673 |
| Nancy Simonian | PSU | — | 118,700 | — | 924,673 |
| Nancy Simonian | Option | 3,766 | — | 30.4 | — |
| Nancy Simonian | Option | 3,483 | — | 30.4 | — |
| Nancy Simonian | Option | 2,152 | — | 30.4 | — |
| Nancy Simonian | Option | 7,916 | — | 85.13 | — |
| Nancy Simonian | Option | 28,500 | — | 67.1 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Peter WirthIndependent | $80,000 | $14,800 | $15,604 | — | $0 | $110,404 |
| Marsha H. FanucciIndependent | 54,375 | 14,800 | 15,604 | — | 0 | 84,779 |
| S. Gail EckhardtIndependent | 52,000 | 14,800 | 15,604 | — | 0 | 82,404 |
| Richard A. YoungIndependent | 51,750 | 14,800 | 15,604 | — | 0 | 82,154 |
| Deborah DunsireIndependent | 48,670 | 14,800 | 15,604 | — | 0 | 79,074 |
| Andrew M. OhIndependent | 48,125 | 14,800 | 15,604 | — | 0 | 78,154 |
| Timothy C. TysonIndependent | 45,625 | 14,800 | 15,604 | — | 0 | 76,029 |
| Mark J. AllesIndependent | 35,625 | 14,800 | 15,604 | — | 0 | 66,029 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $416,170 |
| Equity awards (grant-date value) | $118,400 |
| All other compensation | $0 |
| Total cost of the board | $534,570 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Syros Pharmaceuticals as a peer
Companies that benchmark against SYRS
4 companies name SYRS as a compensation peer
The list of companies that name SYRS as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Syros Pharmaceuticals, Inc. | 2023 | Conley Chee | $479,092 | $369,460 | $0 | $192,455 | $1,041,697 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-05 | 17,127,081 | 359,883 | 20,397 | 97.94% | Passed |
| 2023 | 2023-06-01 | 8,112,398 | 1,252,885 | 100,127 | 86.62% | Passed |
| 2022 | 2022-06-01 | 38,974,415 | 1,485,752 | 132,765 | 96.33% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-06-05 | 97.94%a |
| 2023 | 2023-06-01 | 86.62%b |
| 2022 | 2022-06-01 | 96.33%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Srinivas Akkaraju | Director | 2024-06-01 | D | 4,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2024-06-01 | A | 4,000 | — | — | Common | Form 4 ↗ |
| Deborah Dunsire | Director | 2024-06-01 | D | 4,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Deborah Dunsire | Director | 2024-06-01 | A | 4,000 | — | — | Common | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2024-06-05 | A | 4,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2024-06-05 | A | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Wirth | Director | 2024-06-05 | A | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Wirth | Director | 2024-06-05 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Marsha H. Fanucci | Director | 2024-06-05 | A | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marsha H. Fanucci | Director | 2024-06-05 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Andrew M. Oh | Director | 2024-06-05 | A | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew M. Oh | Director | 2024-06-05 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| S. Gail Eckhardt | Director | 2024-06-05 | A | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| S. Gail Eckhardt | Director | 2024-06-05 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Deborah Dunsire | Director | 2024-06-05 | A | 4,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Deborah Dunsire | Director | 2024-06-05 | A | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy C. Tyson | Director | 2024-06-05 | A | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy C. Tyson | Director | 2024-06-05 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Richard A. Young | Director | 2024-06-05 | A | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard A. Young | Director | 2024-06-05 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Nancy Simonian | Director | 2024-06-05 | A | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy Simonian | Director | 2024-06-05 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Richard A. Young | Director | 2024-06-28 | D | 34,837 | 5 | 178,365 | Common | Form 4 ↗ |
| Conley Chee | Director | 2024-09-10 | A | 50,000 | 2 | 75,260 | Common | Form 4 ↗ |
| Jason Haas | Chief Financial Officer | 2024-09-10 | A | 35,363 | 2 | 54,788 | Common | Form 4 ↗ |
| Conley Chee | Director | 2024-09-11 | A | 50,000 | 2 | 85,420 | Common | Form 4 ↗ |
| Jason Haas | Chief Financial Officer | 2024-09-11 | A | 19,293 | 2 | 30,446 | Common | Form 4 ↗ |
| Jason Haas | Chief Financial Officer | 2024-09-12 | A | 45,344 | 2 | 76,006 | Common | Form 4 ↗ |
| Richard A. Young | Director | 2024-09-16 | D | 2,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard A. Young | Director | 2024-09-16 | A | 2,667 | — | — | Common | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2024-09-16 | D | 2,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Srinivas Akkaraju | Director | 2024-09-16 | A | 2,667 | — | — | Common | Form 4 ↗ |
| Gerald E. Quirk | Chief Legal & Compliance Offic | 2024-09-30 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gerald E. Quirk | Chief Legal & Compliance Offic | 2024-09-30 | D | 3,100 | 2 | 6,510 | Common | Form 4 ↗ |
| Gerald E. Quirk | Chief Legal & Compliance Offic | 2024-09-30 | A | 10,000 | — | — | Common | Form 4 ↗ |
| Kristin Stephens | Chief Development Officer | 2024-10-31 | D | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kristin Stephens | Chief Development Officer | 2024-10-31 | D | 6,104 | 2 | 12,757 | Common | Form 4 ↗ |
| Kristin Stephens | Chief Development Officer | 2024-10-31 | A | 17,000 | — | — | Common | Form 4 ↗ |
| Conley Chee | Director | 2024-10-31 | D | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Conley Chee | Director | 2024-10-31 | D | 8,707 | 2 | 18,198 | Common | Form 4 ↗ |
| Conley Chee | Director | 2024-10-31 | A | 17,000 | — | — | Common | Form 4 ↗ |
| Jason Haas | Chief Financial Officer | 2024-10-31 | D | 18,875 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Haas | Chief Financial Officer | 2024-10-31 | D | 5,624 | 2 | 11,754 | Common | Form 4 ↗ |
| Jason Haas | Chief Financial Officer | 2024-10-31 | A | 18,875 | — | — | Common | Form 4 ↗ |
| David Roth | Chief Medical Officer | 2024-10-31 | D | 18,875 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Roth | Chief Medical Officer | 2024-10-31 | D | 6,776 | 2 | 14,162 | Common | Form 4 ↗ |
| David Roth | Chief Medical Officer | 2024-10-31 | A | 18,875 | — | — | Common | Form 4 ↗ |
| Nancy Simonian | Director | 2024-10-31 | D | 40,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy Simonian | Director | 2024-10-31 | A | 40,125 | — | — | Common | Form 4 ↗ |
| Jason Haas | Chief Financial Officer | 2024-11-18 | D | 137,803 | 0 | 28,980 | Common | Form 4 ↗ |
| Conley Chee | Director | 2024-11-18 | D | 134,797 | 0 | 26,932 | Common | Form 4 ↗ |
| David Roth | Chief Medical Officer | 2024-11-18 | D | 12,099 | 0 | 2,382 | Common | Form 4 ↗ |
| Kristin Stephens | Chief Development Officer | 2024-11-18 | D | 36,133 | 0 | 7,949 | Common | Form 4 ↗ |
| Gerald E. Quirk | Chief Legal & Compliance Offic | 2024-11-19 | D | 46,657 | 0 | 10,321 | Common | Form 4 ↗ |
| Nancy Simonian | Director | 2024-11-25 | D | 134,713 | 0 | 35,739 | Common | Form 4 ↗ |
| Nancy Simonian | Director | 2024-12-02 | D | 37,070 | 0 | 10,016 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (75 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Nancy Simonian. 10-K, filed 2024-04-23. Section “Executive Compensation”. As printed: 1,436,782. View filing ↗
- Section 01, Conley Chee. 10-K, filed 2024-04-23. Section “Executive Compensation”. As printed: 1,041,697. View filing ↗
- Section 01, Eric Olson. 10-K, filed 2024-04-23. Section “Executive Compensation”. As printed: 935,768. View filing ↗
- Section 01, David Roth. 10-K, filed 2024-04-23. Section “Executive Compensation”. As printed: 876,534. View filing ↗
- Section 01, Jason Haas. 10-K, filed 2024-04-23. Section “Executive Compensation”. As printed: 833,019. View filing ↗
- Section 08, Peter Wirth. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 110,404. View filing ↗
- Section 08, Marsha H. Fanucci. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 84,779. View filing ↗
- Section 08, S. Gail Eckhardt. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 82,404. View filing ↗
- Section 08, Richard A. Young. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 82,154. View filing ↗
- Section 08, Deborah Dunsire. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 79,074. View filing ↗
- Section 08, Andrew M. Oh. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 78,154. View filing ↗
- Section 08, Timothy C. Tyson. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 76,029. View filing ↗
- Section 08, Mark J. Alles. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 66,029. View filing ↗
- Section 02, Srinivas Akkaraju 2024-06-01. Form 4, filed 2024-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2024-06-01. Form 4, filed 2024-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Dunsire 2024-06-01. Form 4, filed 2024-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Dunsire 2024-06-01. Form 4, filed 2024-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Wirth 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Wirth 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marsha H. Fanucci 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marsha H. Fanucci 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew M. Oh 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew M. Oh 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, S. Gail Eckhardt 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, S. Gail Eckhardt 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Dunsire 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deborah Dunsire 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy C. Tyson 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy C. Tyson 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard A. Young 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard A. Young 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy Simonian 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy Simonian 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard A. Young 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Conley Chee 2024-09-10. Form 4, filed 2024-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2024-09-10. Form 4, filed 2024-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Conley Chee 2024-09-11. Form 4, filed 2024-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2024-09-11. Form 4, filed 2024-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2024-09-12. Form 4, filed 2024-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard A. Young 2024-09-16. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard A. Young 2024-09-16. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2024-09-16. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Srinivas Akkaraju 2024-09-16. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gerald E. Quirk 2024-09-30. Form 4, filed 2024-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gerald E. Quirk 2024-09-30. Form 4, filed 2024-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gerald E. Quirk 2024-09-30. Form 4, filed 2024-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristin Stephens 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristin Stephens 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristin Stephens 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Conley Chee 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Conley Chee 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Conley Chee 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Roth 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Roth 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Roth 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy Simonian 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy Simonian 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2024-11-18. Form 4, filed 2024-11-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Conley Chee 2024-11-18. Form 4, filed 2024-11-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Roth 2024-11-18. Form 4, filed 2024-11-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristin Stephens 2024-11-18. Form 4, filed 2024-11-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gerald E. Quirk 2024-11-19. Form 4, filed 2024-11-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy Simonian 2024-11-25. Form 4, filed 2024-11-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy Simonian 2024-12-02. Form 4, filed 2024-12-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-06. Item 5.07 · say-on-pay result. As reported: 97.94% (votes for as printed: 17,127,081). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-02. Item 5.07 · say-on-pay result. As reported: 86.62% (votes for as printed: 8,112,398). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-06-07. Item 5.07 · say-on-pay result. As reported: 96.33% (votes for as printed: 38,974,415). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 416,170 + equity 118,400 + all other 0 = 534,570, summed across the director compensation table rows.
- Syros Pharmaceuticals, Inc. (subject), Section 10b CEO total. 10-K, filed 2024-04-23. CEO total compensation as printed in Syros Pharmaceuticals, Inc.'s own proxy. As printed: 1,041,697. View filing ↗